* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studiesBekinda® (RHB-102) and Yeliva® (Opaganib) are proposed tradenames which are subject to FDA review and approvalTalicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment ofinfection in adults. For full prescribing information see: here Movantik(naloxegol) is indicated for the treatment of opioid induced constipation (OIC) in adults with chronic non cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. For full prescribing information see: here Aemcolo® (rifamycin) is indicated for the treatment of travelers diarrhea caused by noninvasive strains ofin adults. For full prescribing information see: here